Health Care • Biotechnology: Pharmaceutical Preparations
$84.91 ▼ -1.68
(-1.94%)
MKT CAP: $7.56B • VOL: 730.4K
52W L $70 52W H $149
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$71
MEDIAN
$95
MEAN
$97
HIGH
$115
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ABVX TAPE
ABVX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $102.74 | $97.65 | 2025-02-14 | $77.27 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $106.99 | $100.19 | 2025-02-06 | $79.82 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $96.80 | $93.40 | 2025-01-29 | $81.51 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $86.61 | — | 2025-01-17 | $83.21 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $74.72 | $80.66 | 2025-01-09 | $75.57 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $101.04 | $88.31 | 2024-12-18 | $73.87 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $82.36 | $85.76 | 2024-12-04 | $78.97 | -4.3% | 48% | C |